Camurus AB/Skr CAMX
08:00
16:05
00:15
08:20
16:25
1D1W1MYTD1Y5YMAX
About Camurus AB
Camurus AB is a biopharmaceutical company headquartered in Lund, Sweden, specializing in the development of innovative pharmaceuticals for the treatment of serious and chronic diseases. The company's core offerings focus on proprietary drug delivery technologies, including FluidCrystal® technology, which enhances the therapeutic benefits and delivery of active ingredients. Camurus concentrates its efforts on areas such as addiction treatment, pain management, and oncology, aiming to improve patient outcomes through advanced formulations. The company operates in several international markets, leveraging strategic partnerships and a focused product pipeline to maintain its position within the biopharmaceutical industry. Its operations are characterized by a strong emphasis on research and development to sustain and expand its portfolio.
Ticker
Skr CAMX
Sector
Primary listing
XSTO
Employees
280
Headquarters
Lund, Sweden
Website
Camurus AB Metrics
BasicAdvanced
kr 41B
53.10
kr 13.04
0.44
-
Price and volume
Market cap
kr 41B
Beta
0.44
52-week high
kr 754.50
52-week low
kr 483.80
Average daily volume
127K
Financial strength
Current ratio
10.607
Quick ratio
9.941
Long term debt to equity
2.106
Total debt to equity
2.582
Interest coverage (TTM)
210.09%
Profitability
EBITDA (TTM)
931.579
Gross margin (TTM)
93.50%
Net profit margin (TTM)
33.21%
Operating margin (TTM)
39.15%
Effective tax rate (TTM)
21.24%
Revenue per employee (TTM)
kr 8,410,000
Management effectiveness
Return on assets (TTM)
14.06%
Return on equity (TTM)
21.63%
Valuation
Price to earnings (TTM)
53.097
Price to revenue (TTM)
17.349
Price to book
10.01
Price to tangible book (TTM)
10.01
Price to free cash flow (TTM)
67.56
Free cash flow yield (TTM)
1.48%
Free cash flow per share (TTM)
10.25
Growth
Revenue change (TTM)
39.37%
Earnings per share change (TTM)
189.50%
3-year revenue growth (CAGR)
39.29%
10-year revenue growth (CAGR)
24.49%
3-year earnings per share growth (CAGR)
195.61%
10-year earnings per share growth (CAGR)
19.89%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Camurus AB stock?
Camurus AB (CAMX) has a market cap of Skr41B as of January 29, 2026.
What is the P/E ratio for Camurus AB stock?
The price to earnings (P/E) ratio for Camurus AB (CAMX) stock is 53.1 as of January 29, 2026.
Does Camurus AB stock pay dividends?
No, Camurus AB (CAMX) stock does not pay dividends to its shareholders as of January 29, 2026.
When is the next Camurus AB dividend payment date?
Camurus AB (CAMX) stock does not pay dividends to its shareholders.
What is the beta indicator for Camurus AB?
Camurus AB (CAMX) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.